Nasdaq GlobeNewswire

Minerva Provides Year-End Update on Clinical Trials With Three Central Nervous System Product Candidates


WALTHAM, Mass., 2015-12-09 14:30 CET (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today provided a year-end update on clinical trials testing MIN-101 for schizophrenia, MIN-202 for insomnia disorder and adjunctive treatment of major depressive disorder (MDD) and MIN-117 for MDD.

"Our primary focus during 2015 has been on clinical trial execution, and we are pleased with the pace of patient recruitment that has taken place in all four ongoing trials," said Dr. Remy Luthringer, president and chief executive officer of Minerva. "The progress achieved during the past year paves the way for a series of topline data readouts during the first six months of 2016."


In the randomized, placebo-controlled double-blind Phase IIb trial with MIN-101 for schizophrenia, the Company has reached its patient screening target and expects to achieve its enrollment target of 234 patients in late December, 2015. The primary objective of this trial is to evaluate the efficacy of MIN-101 compared to placebo in improving the negative symptoms of schizophrenic patients over 12 weeks of treatment. Patients who respond positively to treatment with MIN-101 will have the opportunity to enter an extension period of six months, during which all patients will be on active treatment. Topline results for the core 12-week treatment evaluation period are expected in the second quarter of 2016.

MIN-202 (JNJ-42847922)

Patient enrollment has been completed in two trials with MIN-202, under joint development with Janssen Pharmaceutica NV. These include a Phase IIa trial in insomnia disorder and a Phase Ib trial in adjunctive treatment of MDD.

The Phase IIa trial in insomnia disorder is a randomized, placebo-controlled double-blind study to evaluate treatment with MIN-202 in 26 patients with insomnia disorder without psychiatric co-morbidity. The primary endpoint is sleep efficiency as measured by polysomnography, with secondary endpoints including additional assessments of sleep, mood and cognition, as well as safety.

The Phase Ib trial in adjunctive treatment of MDD is a randomized, diphenhydramine- and placebo-controlled double-blind trial to evaluate treatment with MIN-202 in 48 patients with MDD. The primary endpoint is safety, and secondary endpoints include assessments of depressive symptomology, cognition and sleep.


The Company is continuing to screen and randomize patients in a Phase IIa trial with MIN-117 to treat MDD. The trial is comparing the therapeutic impact of two doses of MIN-117 to paroxetine and placebo. Target enrollment is 80 patients, with 20 patients expected in each of the four groups. The primary endpoint is the efficacy of MIN-117 versus placebo in reducing depressive symptoms. Topline results are expected in the first half of 2016.

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva's proprietary compounds include: MIN-101, in Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), in Phase IIa and Phase Ib development for insomnia and adjunctive MDD, respectively; MIN-117, in development for MDD; and MIN-301, in pre-clinical development for Parkinson's disease. Minerva's common stock is listed on the NASDAQ Global Market under the symbol "NERV." For more information, please visit

Forward-Looking Safe Harbor Statement

This press release contains forward-looking statements which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, reflect management's expectations as of the date of this press release, and involve certain risks and uncertainties. Forward-looking statements include statements herein with respect to the timing and results of future clinical milestones; the timing of future clinical trials and results of clinical trials; the clinical and therapeutic potential of our compounds; our ability to successfully develop and commercialize our therapeutic products; the sufficiency of our current cash position to fund our operations; and management's ability to successfully achieve its goals. These forward-looking statements are based on our current expectations and may differ materially from actual results due to a variety of factors including, without limitation, our ability to successfully enroll patients in ongoing and future clinical trials; the safety and efficacy of our product candidates observed in clinical development; our ability to accurately forecast the costs associated with ongoing and future clinical trials; and our ability to raise additional capital to fund our operations on terms acceptable to us or at all. These and other potential risks and uncertainties that could cause actual results to differ from the results predicted are more fully detailed under the caption "Risk Factors" in our filings with the Securities and Exchange Commission, including our Quarterly Report on Form 10-Q for the quarter ended September 30, 2015, filed with the Securities and Exchange Commission on November 5, 2015. Copies of reports filed with the SEC are posted on our website at The forward-looking statements in this press release are based on information available to us as of the date hereof, and we disclaim any obligation to update any forward-looking statements, except as required by law.

         CONTACT: William B. Boni
         VP, Investor Relations/
         Corp. Communications
         Minerva Neurosciences, Inc.
         (617) 600-7376

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

NRT Acquires OfferCraft, Award-Winning Provider of Artificial Intelligence, Gamification and Digital Content Solutions20.3.2018 14:22Pressemelding

Acquisition of hyper-engagement platform enhances NRT's ability to deliver transformative, revenue-generating technology to its customers LAS VEGAS, March 20, 2018 (GLOBE NEWSWIRE) -- NRT Technology Corp. ("NRT"), a leading provider of digital commerce experiences in gaming and financial services, announced that it has acquired the assets of privately held OfferCraft, a software company that uses artificial intelligence and gamification to drive loyalty, engagement and revenue. Terms of the agreement are not disclosed. The deal will allow NRT to integrate OfferCraft's patent-pending solutions into its existing kiosk, mobile, table games and cashless payment product lines, while also expanding into entirely new areas across nearly every digital channel. OfferCraft's artificial intelligence software allows offers, coupons and rewards to be distributed digitally across email, SMS, websites, social media, kiosks, the Point of Sale, signage, and more. Unlike traditional marketing content, t

Millennial Esports' Eden Games Amongst First Studios to Integrate Amazon GameOn20.3.2018 13:58Pressemelding

Millennial's game studio brings competitions to Gear.Club fans through Amazon GameOn TORONTO, March 20, 2018 (GLOBE NEWSWIRE) -- Millennial Esports Corp. ("Millennial" or the "Company") (TSX VENTURE:GAME) (OTCQB:MLLLF), a mobile video game publisher focused on Esports and Racing, today announced that the Millennial Esports mobile racing game, Gear.Club, is expanding its gaming experience with the integration of Amazon GameOn, a new cross-platform competitive gaming service. After working with Amazon to integrate with this new service, Millennial Esports' game studio, Eden Games, was announced at the Game Developers Conference (GDC) on March 19 as one of the first game studios to build the service into one of their games. "Supported by this amazing new Amazon service, we can now offer daily Gear.Club Esports Racing competitions with real-world prizes fulfilled by Amazon. By being an early adopter of Amazon's cross-platform, competitive gaming service, we are excited to provide our fans

Elemica Releases New Connect and Automate Solutions for the Digital Supply Network20.3.2018 13:03Pressemelding

Elemica QuickLink Email P2P and Elemica QuickLink Email Logistics Provides Automated Purchase Order, Invoice, and Shipment Confirmations WAYNE, Pa., March 20, 2018 (GLOBE NEWSWIRE) -- Elemica, the leading Digital Supply Network for process manufacturers, announces new Elemica QuickLink solutions to help clients extend the connection and automation capabilities with their suppliers and logistics providers without requiring time-consuming integration services. The new Elemica QuickLink Email solutions allow clients to onboard their suppliers and logistics service providers cost effectively by connecting and automating their buying and shipping processes through email. Elemica QuickLink Email P2P enables buyers and suppliers to send and confirm purchase orders and invoices automatically with each other, while QuickLink Email Logistics allows shippers to request and confirm shipments with their logistics service providers through email. Supply chain partners that typically use manual proce

Genomatica brings its naturally sourced Brontide(TM) butylene glycol to Europe20.3.2018 13:00Pressemelding

Azelis chosen to distribute; already confirming better personal care formulations SAN DIEGO and ANTWERP, Belgium, March 20, 2018 (GLOBE NEWSWIRE) -- Genomatica, a widely-recognized technology leader for naturally sourced chemicals, and Azelis, a leading distributor of specialty chemicals, announced that Azelis is now the exclusive distributor for personal care applications of Genomatica's naturally sourced, award-winning Brontide(TM) butylene glycol in Europe. Azelis is already seeing widespread interest in Brontide from major brands and plans to support scores of major customers during Brontide's market introduction. See Brontide introduction video. Photos accompanying this announcement are available at A naturally sourced, sustainable cosmetics ingredient; Brontide honored for innovation Butylene glycol, a colo

LexinFintech Holdings Ltd. Reports Fourth Quarter and Full Year 2017 Unaudited Financial Results20.3.2018 12:22Pressemelding

SHENZHEN, China, March 20, 2018 (GLOBE NEWSWIRE) -- LexinFintech Holdings Ltd. ("Lexin" or the "Company") (NASDAQ:LX), a leading online consumer finance platform for educated young adults in China, today announced its unaudited financial results for the fourth quarter and full year ended December 31, 2017. Fourth Quarter and Full Year 2017 Operational Highlights: Total loan originations in 2017 reached RMB47.7 billion, representing an increase of 115% from RMB22.2 billion in 2016. Total outstanding principal balance of loans reached RMB19.3 billion as of December 31, 2017, representing an increase of 94.7% from RMB9.9 billion as of December 31, 2016. The weighted average tenor of loans originated on our platform in 2017 was approximately 9.53 months. The effective APR1 was 22.8% for the fourth quarter of 2017. Customer acquisition cost2 amounted to RMB99 in 2017, representing a decrease of 22% from 127 in 2016. Total number of registered users reached 23.9 million as of December 31, 20

Merus and the Vall d'Hebron Institute of Oncology Announce Research Collaboration to Develop Innovative Bispecific Antibodies for Therapeutic Applications in the Treatment of Cancer20.3.2018 12:00Pressemelding

UTRECHT, The Netherlands, March 20, 2018 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody therapeutics (Biclonics®), and the Vall d'Hebron Institute of Oncology (VHIO), a leading comprehensive cancer center of excellence located in Barcelona, Spain, today announced a strategic research collaboration to develop novel agents for therapeutic applications. The collaboration will combine Merus' proprietary Biclonics® technology platform and VHIO's expertise in clinical, translational and preclinical research. Josep Tabernero, M.D., Ph.D., M.Sc., Director of VHIO, has served as a scientific advisor to Merus for the past six years. "VHIO is an internationally renowned leader in cancer research. This new collaboration builds on the successful working relationship established in the Phase 1/2 study for MCLA-128, a Biclonics® targeting HER3 signaling, and in the preclinical evaluation of MCLA-158, a Biclonics® target

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom